Back to ABBV Overview
NYQ · Valuation Lab
ABBV
AbbVie Inc.
Last$246.20
Market cap435.1B
EV/EBITDA16.1x
Intrinsic value
$213.42
MoS -15.4% · Fairly Valued
Assuming 15.0% FCF margin and 10.2% Y1–5 growth.
Upside to price
EV (DCF)440.7B
Terminal share75%
Expected IV$210.69
Probability weights
Projected free cash flows
Stage FCF path with present values · terminal 75% of EV
PV of stage FCFs111.5B
PV of terminal value329.2B
Enterprise value440.7B
Net cash / (debt)-63.5B
Equity value377.1B
Intrinsic value / share$213.42
| Year | Revenue | FCF | PV | DF |
|---|---|---|---|---|
| Y1 | 71B | 10.6B | 10B | 94.3% |
| Y2 | 78.2B | 11.7B | 10.4B | 89.0% |
| Y3 | 86.2B | 12.9B | 10.9B | 84.0% |
| Y4 | 95B | 14.2B | 11.3B | 79.2% |
| Y5 | 104.6B | 15.7B | 11.7B | 74.7% |
| Y6 | 110B | 16.5B | 11.6B | 70.5% |
| Y7 | 115.6B | 17.3B | 11.5B | 66.5% |
| Y8 | 121.5B | 18.2B | 11.4B | 62.7% |
| Y9 | 127.7B | 19.2B | 11.3B | 59.2% |
| Y10 | 134.2B | 20.1B | 11.2B | 55.8% |
| Terminal | — | — | 329.2B | — |
Educational DCF model only — not financial advice. Terminal value and assumptions dominate results; verify filings and run your own diligence.